Sucroferric Oxyhydroxide Generics Suppliers & Bulk Manufacturers
Available Forms: Chewable Tablet
Available Strengths: 500mg
Reference Brands: Velphoro® (EU & US)
Category:
Nephrology
Sucroferric oxyhydroxide is an iron-based phosphate binder used to control high blood phosphate levels in dialysis patients with chronic kidney disease. It is approved in the EU and US and offers a low pill burden and strong efficacy for nephrology care.
Sucroferric oxyhydroxide Generics is available in Chewable Tablet
and strengths such as 500mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Sucroferric oxyhydroxide Generics is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Sucroferric oxyhydroxide Generics can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Sucroferric oxyhydroxide is a next-generation, iron-based phosphate binder widely used in the nephrology sector for managing hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis. With a strong safety profile and proven efficacy, it offers a convenient, low-pill burden option compared to traditional binders. The product is in high demand across EU and US B2B pharmaceutical markets, driven by rising CKD prevalence and increasing dialysis patient numbers. Ideal for licensing, distribution, and contract manufacturing partnerships, sucroferric oxyhydroxide presents a strategic opportunity for companies targeting renal care therapeutics in regulated markets. Secure your position in this growing nephrology segment today.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing